Managed Healthcare Executive September 27, 2018
In a session on Tuesday, September 25, 2018, John Price, CEO of OptumRX, presented at a session titled “The Drug Pricing Debate.”
At the session, Mr Price highlighted the current industry landscape. He addressed opportunities around innovation, and ultimately discussed how PBMs and pharma can and should work together to advance therapies for patients and payers.
According to “Blueprint to Lower Drug Prices” created by President Donald Trump and his administration, current drug prices are supposed to decrease and drug companies are to voluntarily cut drug prices. However, since the announcement of the blueprint in May, there have actually been more price hikes than cuts a report by AP found.
For the analysis, AP analyzed 26,176 US list price changes...
Today's Sponsors
Today's Sponsor